A variety of biomarkers have been developed to identify cancer patients who would benefit from ICIs, such as PD-L1 expression (Topalian et al., 2012; Gibney et al., 2016), tumor mutational burden (TMB) (Yarchoan et al., 2017; Hellmann et al., 2018), microsatellite instability (MSI) status (Le et al., 2017), and tumor-infiltrating lymphocytes (TILs) (Tumeh et al., 2014; Sade-Feldman et al., 2018). The gene discussed is CD274; the disease is neoplasm.